WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H555262
CAS#: 713121-80-3
Description: ML-193, also known as CID 1261822, is a potent antagonist of GPR55 (IC50 = 221 nM).
Hodoodo Cat#: H555262
Name: ML-193
CAS#: 713121-80-3
Chemical Formula: C28H25N5O4S
Exact Mass: 527.16
Molecular Weight: 527.599
Elemental Analysis: C, 63.74; H, 4.78; N, 13.27; O, 12.13; S, 6.08
Synonym: ML-193; ML 193; ML193; CID 1261822; CID-1261822; CID1261822.
IUPAC/Chemical Name: N-[4-[[(3,4-Dimethyl-5-isoxazolyl)amino]sulfonyl]phenyl]-6,8-dimethyl-2-(2-pyridinyl)-4-quinolinecarboxamide
InChi Key: HTSLEZOTMYUPLU-UHFFFAOYSA-N
InChi Code: InChI=1S/C28H25N5O4S/c1-16-13-17(2)26-22(14-16)23(15-25(31-26)24-7-5-6-12-29-24)27(34)30-20-8-10-21(11-9-20)38(35,36)33-28-18(3)19(4)32-37-28/h5-15,33H,1-4H3,(H,30,34)
SMILES Code: O=C(C1=CC(C2=NC=CC=C2)=NC3=C(C)C=C(C)C=C13)NC4=CC=C(S(=O)(NC5=C(C)C(C)=NO5)=O)C=C4
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
Biological target: | |
In vitro activity: | |
In vivo activity: |
Solvent | Max Conc. mg/mL | Max Conc. mM | |
---|---|---|---|
Solubility | |||
DMSO | 52.8 | 100.00 |
The following data is based on the product molecular weight 527.60 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
Formulation protocol: | |
In vitro protocol: | |
In vivo protocol: |
1: Leo LM, Familusi B, Hoang M, Smith R, Lindenau K, Sporici KT, Brailoiu E, Abood ME, Brailoiu GC. GPR55-mediated effects on brain microvascular endothelial cells and the blood-brain barrier. Neuroscience. 2019 Aug 21;414:88-98. doi: 10.1016/j.neuroscience.2019.06.039. Epub 2019 Jul 4. PMID: 31279825; PMCID: PMC6684354.
2: Deliu E, Sperow M, Console-Bram L, Carter RL, Tilley DG, Kalamarides DJ, Kirby LG, Brailoiu GC, Brailoiu E, Benamar K, Abood ME. The Lysophosphatidylinositol Receptor GPR55 Modulates Pain Perception in the Periaqueductal Gray. Mol Pharmacol. 2015 Aug;88(2):265-72. doi: 10.1124/mol.115.099333. Epub 2015 May 13. PMID: 25972448; PMCID: PMC4518086..